Nature | Editorial

Double vision

Scientists must ensure that they take the lead in the ethical debate surrounding the therapeutic use of stem cells derived from human clones.

Article tools

Last week’s announcement in Cell that a team in Oregon has successfully derived stem cells from a cloned human embryo raises many questions. Researchers must do their best to answer them. If they do not, then they risk a repeat performance of the misinformation, confusion and distraction that followed the birth in 1996 of the first mammalian clone, Dolly the sheep. Nonsense such as rumours that Saddam Hussein was going to copy himself, claims by the Raëlian sect that it had produced a cloned girl named Eve and declarations by physicist and entrepreneur Richard Seed that he would produce hundreds of thousands of human clones generated an environment of fear that distracted from the real debate and set back research.

The reaction to the Oregon team’s success has been predictably mixed. Some have lauded the achievement, others have been less enthusiastic. “Barbaric,” wrote one critic. Another called it a “terrible injustice”.

“Armies of cloned despots are the last thing we need to worry about.”

It is true that the research faces ethical controversy on three fronts: egg donation, embryo destruction and cloning. The work needs eggs to be donated by women, who must undergo a procedure that carries risks of complications. If the research ultimately produces promising medical therapies, will we see a group of women marshalled to feed this therapeutic intervention? The procedure also requires the destruction of early-stage embryos, which many oppose, usually on religious grounds. And many criticize the fact that the procedure starts down the same path as reproductive cloning, suggesting that to advance the technology will inevitably result in reproductive cloning of humans.

These are serious points and they need to be considered. But the reality is that, if anything, the latest research suggests that the chance of creating a cloned human is more remote than it seemed two weeks ago. No group has put more effort into trying to clone monkeys reproductively than the Oregon scientists. Yet after nearly two decades of trying, they have yet to succeed. They conclude that their method, optimized for producing embryonic stem-cell lines from cloned embryos, probably cannot be used for reproductive cloning.

Still, given the controversy that surrounds this work, some argue that researchers should stick to alternatives such as induced pluripotent stem (iPS) cells. Like cloned stem cells, these offer patient-specific cells with embryo-like developmental potential, but crucially they do not require egg recruitment, embryo destruction or cloning. Leading iPS-cell researchers are now keen to compare these cells with the cloned stem cells to help them to evaluate and improve iPS cells. Until that work is done, it will be hard to say whether iPS cells are, or can be, reprogrammed to function as effectively cloned cells.

But this research will move slowly, at least in the United States. Because production of the cloned cells requires the destruction of embryos specifically created for research, US laboratories funded by the taxpayer through the National Institutes of Health cannot use the technique, nor can they work with the stem cells created by it. Progress will depend on the few laboratories with sufficient private funds.

Whatever the outcome of those investigations, there are some clinical applications for which cloned stem cells could be the best option. Cloned cells contain the nuclear DNA of whoever is being cloned but they also hold the mitochondrial DNA from the egg donor, which means that they could be used to correct defective mitochondrial DNA. That may pave the way to treatments for genetic diseases such as Leber’s hereditary optic neuropathy. Such applications should not be hyped. Like any stem-cell therapy, the hurdles are high. Is it possible to get functioning cells to the right place and to make sure that they continue to work? Can enough of the cells with faulty mitochondrial DNA be replaced by the cloned ones?

Experiments that follow up on the Oregon team’s advance will be especially valuable. If they don’t prove that the technique is worth the controversy, it will no doubt fall into disuse. If it does prove to have therapeutic promise, questions of egg donation will need to be re-evaluated. Either way, armies of clones or cloned despots are the last thing we need to worry about.

Journal name:
Nature
Volume:
497,
Pages:
409
Date published:
()
DOI:
doi:10.1038/497409a

For the best commenting experience, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will see comments updating in real-time and have the ability to recommend comments to other users.

Comments

Commenting is currently unavailable.

sign up to Nature briefing

What matters in science — and why — free in your inbox every weekday.

Sign up

Listen

new-pod-red

Nature Podcast

Our award-winning show features highlights from the week's edition of Nature, interviews with the people behind the science, and in-depth commentary and analysis from journalists around the world.